Pharmaceuticals News and Research

RSS

Certain Chinese medicines can regulate neurotrophic and apoptosis-related factors

Parkinson's disease is a common neurodegenerative disease in the elderly, which is pathologically characterized by selective loss of dopaminergic neurons. Compound preparations of Chinese medicines that can tonify the kidney have been reported to significantly improve symptoms of Parkinson's disease.

28 Nov 2013

PLOS and DNDi to launch collection of neglected tropical diseases at 10-year anniversary of DNDi

As part of a collaborative initiative, PLOS and the Drugs for Neglected Diseases initiative (DNDi) are delighted to be launching a special Collection-PLOS & DNDi: a decade of Open Access and Neglected Tropical Diseases R&D (Research and Development)-to coincide with a joint event at the Institut Pasteur in Paris celebrating the 10-year anniversary of DNDi.

28 Nov 2013

KKR to acquire minority stake in Gland Pharma for about $200 million

Gland Pharma Limited, a leading Indian pure-play generic injectable pharmaceutical products company, today announced an agreement under which KKR, a leading global investment firm, will acquire a minority stake in the Company for approximately US$200 million, including KKR's acquisition of the entire stake held by Evolvence India Life Sciences Fund, an existing private equity investor in Gland Pharma.

28 Nov 2013

Researchers create breathalyzer that may help control blood sugar

Finger pricks may soon be a thing of the past for diabetics. Researchers at Western New England University have created a breathalyzer that may help control blood sugar by measuring the amount of acetone in the breath.

27 Nov 2013

US may be losing ground as the leader in biomedical research

The United States may be losing ground as the leader in biomedical research and within the next five years will be second to China in the funds it spends for R&D, according to Francis Collins, M.D., Ph.D, director of the National Institutes of Health.

27 Nov 2013

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

People inherit different versions of any particular gene, and some genes affect how patients process and metabolize medicines. This especially holds true for people with cardiovascular (CV) disease. They may be fast, slow or non-metabolizers and might also react badly (with serious adverse events) to certain drug therapies or not at all.

27 Nov 2013

UMass Medical School licenses "anti-gal" technology to Agalimmune

The University of Massachusetts Medical School has licensed "anti-gal" technology developed by Professor of Surgery and Medicine Uri Galili, PhD, to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers. Agalimmune is supported by an investment group comprising Loxbridge Research LLP and Animatrix Capital LLP and is based in London and California.

27 Nov 2013

Isis Pharmaceuticals commences Phase 1 study of ISIS-GSK3Rx for treatment of common viral infection

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study for ISIS-GSK3Rx and earned a $3 million milestone payment from GlaxoSmithKline.

27 Nov 2013

Freiburg scientists discover substance that suppresses unchecked cell division in leukemia cells

Scientists of the University of Freiburg and the Freiburg University Medical Center from the collaborative research center Medical Epigenetics (SFB 992) have discovered a new active substance that inhibits cell division in leukemia cells and could play an important role in the fight against cancer.

27 Nov 2013

Inhibitor compounds could form basis of new treatments for such diseases as MRSA, anthrax

Inhibitor compounds developed by UC Irvine structural biologists and Northwestern University chemists have been shown to bolster the ability of antibiotics to treat deadly bacterial diseases such as MRSA and anthrax.

27 Nov 2013

Researchers develop new microsystem for testing drugs to treat epilepsy, MG and cystic fibrosis

Researchers from the University of Southampton, in collaboration with researchers at the University of Quebec at Montreal, have developed a new microsystem for more efficient testing of pharmaceutical drugs to treat diseases such as cystic fibrosis, MG (myasthenia gravis) and epilepsy.

26 Nov 2013

SIMM and Crown Bioscience collaborate to build MCT center in China

Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS) and Crown Bioscience, Inc., announced today that they have reached an agreement to form a strategic collaboration focused on translational oncology and to join forces to build a mouse clinical trial (MCT) center at Crown Taicang campus, Taicang, Jiangsu province, China --SIMM-Crown Mouse Clinical Trial Center, or SCMC.

26 Nov 2013

Virginia Tech professor named AAAS Fellow for contributions to plant science

John Jelesko, an associate professor of plant pathology, physiology and weed science in the College of Agriculture and Life Sciences at Virginia Tech, has been named a Fellow of the American Association for the Advancement of Science.

26 Nov 2013

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Agalimmune Ltd, a biopharmaceutical company, has been created to develop innovative immunotherapeutics for the treatment of cancer, with a focus on solid tumours.

26 Nov 2013

Two separate studies yield key findings for prevention, diagnosis, treatment and cure for AML

Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients.

26 Nov 2013

Nepstar's revenue increases 7.7% to RMB683.2 million in third quarter 2013

China Nepstar Chain Drugstore Ltd.("Nepstar" or the "Company"), the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the third quarter ended September 30, 2013.

26 Nov 2013

Global health organizations join forces to raise awareness on dangers of fake medicines

Fake medicines increasingly put patients and the general public at risk across the world. In response to this challenge, ten partners who represent healthcare professionals, disease-specific organizations, product-development partnerships, foundations, international financing institutions, as well as the research-based pharmaceutical industry have joined forces to raise awareness about the dangers of fake medicines.

26 Nov 2013

Researchers identify new form of treatment for brain tumor

Glioblastoma is one of the most ominous brain tumors. Despite aggressive surgery, radiation and chemotherapy the outcome of this disease is almost always fatal.

26 Nov 2013

Immune Pharmaceuticals to transfer common stock listing from NASDAQ OMX Stockholm Exchange

Immune Pharmaceuticals Inc. announced today that its common stock has been approved for trading on NASDAQ OMX First North Premier, Stockholm ("First North").

26 Nov 2013

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.

25 Nov 2013

Pharmaceuticals News and Research

Certain Chinese medicines can regulate neurotrophic and apoptosis-related factors

PLOS and DNDi to launch collection of neglected tropical diseases at 10-year anniversary of DNDi

KKR to acquire minority stake in Gland Pharma for about $200 million

Researchers create breathalyzer that may help control blood sugar

US may be losing ground as the leader in biomedical research

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

UMass Medical School licenses "anti-gal" technology to Agalimmune

Isis Pharmaceuticals commences Phase 1 study of ISIS-GSK3Rx for treatment of common viral infection

Freiburg scientists discover substance that suppresses unchecked cell division in leukemia cells

Inhibitor compounds could form basis of new treatments for such diseases as MRSA, anthrax

Researchers develop new microsystem for testing drugs to treat epilepsy, MG and cystic fibrosis

SIMM and Crown Bioscience collaborate to build MCT center in China

Virginia Tech professor named AAAS Fellow for contributions to plant science

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Two separate studies yield key findings for prevention, diagnosis, treatment and cure for AML

Nepstar's revenue increases 7.7% to RMB683.2 million in third quarter 2013

Global health organizations join forces to raise awareness on dangers of fake medicines

Researchers identify new form of treatment for brain tumor

Immune Pharmaceuticals to transfer common stock listing from NASDAQ OMX Stockholm Exchange

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence